The effect of Atorvastatin in combination to Tenofovir in the treatment of Hepatitis B

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110621006852N2

Enrollment

Registered

2021-02-28

Start date

2013-04-21

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Disease. Toxic liver disease with hepatitis, not elsewhere classified

Interventions

Intervention 1: Intervention group: Receiver of tenofuir and atorvastatin. Tenofovir is the standard hepatitis B drug and is a reverse transcriptase nucleotide inhibitor. To maintain ethical standards

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with active hepatitis B that are candidates for anti-viral therapy Viral load greater than 100,000 per ml patients with elevated ALT

Exclusion criteria

Exclusion criteria: All patients with severe kidney failure. Patients who use suppressor drugs for immune system. Patients with acquired or congenital immune deficiencies. Patients who have had a history of taking statins or any other antiviral medicines in the last six months.

Design outcomes

Primary

Measure	Time frame
Viral load. Timepoint: At the beginning of the trial and then once every three months interval. Method of measurement: realtime PCR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Haeri

Ghoum University of Medical Sciences

haeri.mr@gmail.com+98 25 3291 7376

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026